Midazolam nasal spray to treat intermittent, stereotypic episodes of frequent seizure activity: pharmacology and clinical role, a comprehensive review

Abstract

An intranasal formulation of midazolam, Nayzilam, has been FDA-approved to treat intermittent, stereotypic episodes of frequent seizure activity. Nayzilam is easy to administer and can quickly treat seizures that occur outside of the hospital. The intra-nasal route of administration allows non-medical personal to administer the drug which makes it more accessible and user-friendly in the event of a seizure. Many studies have indicated quick cessation of seizures with Nayzilam compared to rectal diazepam, which has been the standard of care treatment. Nayzilam has been proven to be safe and effective for acute seizures in children, deeming it a revolutionary alternative in times where intravenous administration is not possible.

 
Cornett EM, Nemomsa MA, Turbeville B, Busby MA, Kaye JS, Kaye AJ, Choi J, Ramirez GF, Varrassi G, et al.
Midazolam nasal spray to treat intermittent, stereotypic episodes of frequent seizure activity: pharmacology and clinical role, a comprehensive review. Health Psychology Research. 2022;10(5). doi:10.52965/001c.38536

Fondazione Paolo Procacci onlus

Via Tacito 7 - 00193 Roma - Email: info@fondazioneprocacci.org

Fondazione Paolo Procacci - Tutti i diritti riservati - Realizzazione Geniomela.it

Privacy e Cookie Policy

Al fine di fornire la migliore esperienza online questo sito utilizza i cookies. Continuando la navigazione nel sito, l'utente ne accetta il nostro utilizzo a fini puramente tecnici.